S100B in cardiac surgery brain monitoring: friend or foe?

Clin Chem Lab Med. 2022 Jan 11;60(3):317-331. doi: 10.1515/cclm-2021-1012. Print 2022 Feb 23.

Abstract

Recent advances in perioperative management of adult and pediatric patients requiring open heart surgery (OHS) and cardiopulmonary bypass (CPB) for cardiac and/or congenital heart diseases repair allowed a significant reduction in the mortality rate. Conversely morbidity rate pattern has a flat trend. Perioperative period is crucial since OHS and CPB are widely accepted as a deliberate hypoxic-ischemic reperfusion damage representing the cost to pay at a time when standard of care monitoring procedures can be silent or unavailable. In this respect, the measurement of neuro-biomarkers (NB), able to detect at early stage perioperative brain damage could be especially useful. In the last decade, among a series of NB, S100B protein has been investigated. After the first promising results, supporting the usefulness of the protein as predictor of short/long term adverse neurological outcome, the protein has been progressively abandoned due to a series of limitations. In the present review we offer an up-dated overview of the main S100B pros and cons in the peri-operative monitoring of adult and pediatric patients.

Keywords: S100B; brain injury; cardiac surgery; cardiopulmonary bypass; neurobiomarker; neuromonitoring.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Biomarkers / metabolism
  • Brain* / metabolism
  • Cardiac Surgical Procedures*
  • Cardiopulmonary Bypass / methods
  • Child
  • Heart Defects, Congenital / etiology
  • Heart Defects, Congenital / metabolism
  • Heart Defects, Congenital / surgery
  • Humans
  • S100 Calcium Binding Protein beta Subunit* / metabolism

Substances

  • Biomarkers
  • S100 Calcium Binding Protein beta Subunit
  • S100B protein, human